Nestle plans to ax hundreds of R&D staffers, shutter big dermatology campus
Three years after Nestle paid $3.6 billion to acquire full control of Galderma, they’re taking an ax to one of its big drug R&D campuses …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
